Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Healthcare stocks are generally more resilient in a challenging macro backdrop compared to stocks in other sectors. This is because the need for medicines and medical treatments i ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...